GlassScriptPhysician profile
Daniel W Sawyer
NPI 1649348913
$4,781.71
in general payments reported to CMS, 2019-2025
32 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $514 · 2021: $754 · 2022: $832 · 2023: $566 · 2024: $766 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $953.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $646.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $551.01 | 2022-2025 | |
| Novo Nordisk INC | $404.27 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $379.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $356.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $295.08 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Amarin Pharma, INC. | $223.94 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $198.32 | 2020-2023 | Xerava, Giapreza |
| Amgen INC. | $160.52 | 2019-2022 | |
| Gilead Sciences, INC. | $77.83 | 2019-2024 | |
| Exact Sciences Corporation | $77.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $54.27 | 2019-2020 | |
| Abbvie INC. | $51.78 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.03 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.31 | 2020-2021 | |
| Allergan, INC. | $29.33 | 2019 | |
| Currax Pharmaceuticals LLC | $28.86 | 2023 | Nexletol, Nexlizet, Contrave |
| Janssen Scientific Affairs, LLC | $22.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.42 | 2025 | Cuvitru |
| Paratek Pharmaceuticals, INC. | $18.01 | 2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.77 | 2019 | |
| Astellas Pharma US INC | $17.69 | 2024 | Veozah |
| Vyera Pharmaceuticals, LLC | $17.64 | 2019 | |
| Philips North America LLC | $17.49 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.94 | 2022 | |
| Medtronic, INC. | $15.30 | 2023 | Minimed 770g |
| Teva Pharmaceuticals USA, INC. | $14.23 | 2022 | |
| Glaxosmithkline, LLC. | $12.51 | 2020 | |
| Melinta Therapeutics, LLC | $12.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sawyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.